MEI Pharma (MEIP)
(Delayed Data from NSDQ)
$3.39 USD
-0.01 (-0.29%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $3.39 0.00 (0.00%) 6:36 PM ET
3-Hold of 5 3
D Value B Growth C Momentum C VGM
Brokerage Reports
MEI Pharma, Inc. [MEIP]
Reports for Purchase
Showing records 21 - 40 ( 141 total )
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
ASCO Abstracts Continue to Support MEI?s Pipeline Strength
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Steady Progress of Pivotal Study With Topline Expected in 1Q21; Reit Buy and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Kyowa Kirin Deal Points to Accelerated Path to Market
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
With Timeline Intact, Study Protocol Amendment Delivers Safer Dosing Schedule; Reit Buy and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Looking Ahead to Several Data Readouts From Multiple Programs; Reit Buy and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Progress on Multiple Fronts; Reit Buy and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
ME-401 May Reinstate the Role of PI3K Inhibition in CLL; Reit Buy and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
ASCO Data Update Continues to Support ME-401?s Superior Safety/Efficacy Balance
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Steady Progress With Multiple Programs Yielding Data; Reit Buy and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Thoughts Around Clinical Progress; Reit Buy and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
We Like MEI?s Pipeline Strength and Diversity; Initiate With Buy and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Healthcare - Biotech: 2018 Epigenetic Almanac
Provider: Roth Capital Partners, Inc.
Analyst: MARANGO J
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Dropping Coverage due to Realignment of Analyst Resources
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Additional ASH Updates for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Pracinostat Granted Breakthrough Therapy Designation Ahead of Ph 3, But Study Financing Remains a Question, Reiterate NEUTRAL and $2 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Ph 3 Pracinostat Study in AML Teed up for 2H16, but Expenses Remain a Concern, Reiterate NEUTRAL and Reducing PT
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
MEIP to Initiate Ph 3 Registration Study for Pracinostat in Newly Diagnosed Elderly AML
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D